ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
This randomized phase III trial studies sunitinib malate to see how well it works compared
to sorafenib tosylate or placebo in treating patients with kidney cancer that has been
removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor
cells that remain after surgery. It is not yet known whether sunitinib malate is more
effective than sorafenib tosylate or placebo in treating kidney cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.